is tirzepatide on shortage there a Major GLP-1 Drug Over. Some Patients Aren't Celebrating A pill could solve the – Minus one of its GLP-1

Verdict at a Glance Both amycretin and CagriSema are Novo Nordisk programs targeting the same GLP-1 plus amylin dual pathway, but with fundamentally different molecular strategies

Slow escalation over 4-week intervals reduces severity by roughly 50%

Notably, mRNA expression of Igfbp genes Igfbp2, Igfbp3 and Igfbp5 was found significantly depleted, and Igfbp4 levels significantly increased upon LLC challenge only in Igf1r fl/fl mice

The SELECT safety analysis found breast cancer rates were marginally lower on semaglutide than placebo, and a 2025 meta-analysis of 50 randomised GLP-1 trials found no increased breast cancer risk